Cerebrolysin (60 mg vial)

Protocol Overview

Concise summary of the regimen.

Dosing & Reconstitution

Administration is subcutaneous and daily, once a day in week 1 and twice a day from week 2 onward. The split is driven by volume: at 20 mg/mL any daily dose above 100 units (1.00 mL) is divided into AM and PM administrations at separate sites, so week 1 is a single 100 unit draw, week 2 is 60 units morning and 60 units evening, week 3 is 70 and 70, and week 4 onward holds at 80 and 80. Sites are rotated systematically across abdomen, thighs, and upper arms to reduce local irritation and avoid lipohypertrophy, and on split-dose days the morning and evening injections use different sites. Injection is slow and steady, with a wait of a few seconds before the needle is withdrawn. Clinical literature describes daily amounts starting around 215 mg, which is 1 mL of the commercial premixed solution, and running up through higher intravenous infusions; this protocol is a deliberately conservative subcutaneous approach with gradual titration, and every unit figure here is calculated for the lyophilized 60 mg vial reconstituted to 20 mg/mL rather than for the premixed ampoule.

Results Timeline

Sequence described in the research record. Individual response varies.

• Week 1: the course opens at 20 mg daily, a single 100 unit draw (1.00 mL), which is the largest volume that still fits one U-100 syringe.
• Week 2: the dose rises to 24 mg daily, 120 units total, which exceeds one syringe and therefore splits into 60 units AM and 60 units PM.
• Week 3: 28 mg daily, 140 units total, given as 70 units AM and 70 units PM.
• Week 4 onward: the maintenance dose of 32 mg daily, 160 units total, given as 80 units AM and 80 units PM and held for the remainder of the course.
• End of course: dosing stops at 8 to 12 weeks, or at 16 weeks where the longer run is chosen.

Reconstitution Steps

1. Draw 3.0 mL bacteriostatic water with a sterile syringe.
2. Inject slowly down the vial wall; avoid foaming.
3. Gently swirl until dissolved (do not shake).
4. Label with date and concentration; refrigerate at 2 to 8 °C, protected from light, and use within 7 days. At 20 mg/mL, 1 unit = 0.01 mL » 200 mcg (0.2 mg) on a U-100 insulin syringe: 20 mg = 100 units, 24 mg = 120 units, 28 mg = 140 units, 32 mg = 160 units.

Storage Instructions

Proper storage preserves peptide quality.

• Lyophilized: store at controlled room temperature at or below 25 °C in dry, dark conditions; do not freeze.
• Reconstituted: refrigerate at 2 to 8 °C, protected from light; use within 7 days; do not freeze.

• Allow vials to reach room temperature before opening to reduce condensation uptake.
• At 3.0 mL per 60 mg vial, one reconstituted vial holds 300 units in total, which is under two days at the 32 mg maintenance dose, so a vial is normally finished well inside the 7 day in-use window.

Supplies Needed

Planning is based on an 8 to 16 week daily protocol with gradual titration, reaching a 32 mg daily maintenance dose, which is 224 mg per week once week 4 is underway.

Peptide Vials (Cerebrolysin, 60 mg vial):

• The master sheet plans about 26 vials for 8 weeks, about 42 vials for 12 weeks, and about 58 vials for 16 weeks, which at 60 mg per vial is roughly 1,560 mg, 2,520 mg, and 3,480 mg of peptide across those courses.

Insulin Syringes (U-100):

• Per week: 7 syringes in week 1 at one injection per day, then 14 per week from week 2 onward once dosing splits into AM and PM.
• 8 weeks: 105 syringes. 12 weeks: 161 syringes. 16 weeks: 217 syringes.

Bacteriostatic Water (10 mL bottles):

• Each 60 mg vial takes 3.0 mL, so one 10 mL bottle of bacteriostatic water covers 3 vials, which works out to 8 bottles for the 26 vials of an 8 week course, 13 bottles for the 42 vials of a 12 week course, and 18 bottles for the 58 vials of a 16 week course.

Alcohol Swabs:

• Per injection: 2 swabs, one for the vial stopper and one for the site, so 14 swabs in week 1 and 28 per week once dosing splits into AM and PM.
• 8 weeks: 210 swabs, which is 3 boxes of 100. 16 weeks: 434 swabs, which is 5 boxes of 100.

Important Notes

Practical considerations for consistency and safety.

• Use new sterile insulin syringes for every injection and dispose of them in a sharps container.
• Rotate injection sites systematically across abdomen, thighs, and upper arms to reduce local irritation, and on AM and PM days use a different site for each of the two administrations.
• Inject slowly and wait a few seconds before withdrawing the needle.
• Document the daily dose, the AM or PM timing, and site rotation to maintain consistency across the course.
• Any daily dose above 100 units (1.00 mL) is split into two separate injections at different sites, which is why every week after the first runs on a twice daily schedule rather than one large draw.
• Regulatory Note: Cerebrolysin is not an approved drug in the United States and is supplied for research and educational purposes only, not for human consumption. The human trial literature in stroke, dementia, and traumatic brain injury was generated with the commercial premixed solution given by intravenous infusion, not with reconstituted lyophilized vials given subcutaneously. The master sheet does not record a WADA classification for this compound.

How This Works

Cerebrolysin is a multicomponent peptide preparation derived from porcine brain tissue, containing biologically active neuropeptides and amino acids with molecular weights below 10 kDa. That low molecular weight allows it to cross the blood-brain barrier and exert neurotrophic effects similar to endogenous factors such as nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF). Preclinical studies demonstrate neuroprotective effects including reduced infarct size and improved recovery in ischemia models. Human trials have examined its use in stroke, dementia, and traumatic brain injury with mixed results but generally favorable tolerability profiles.

Benefits & Side Effects

Observations from the published record.

• Preclinical models consistently show neuroprotective effects including reduced neuronal damage and improved functional recovery after ischemic insult.
• Meta-analyses of human dementia trials suggest modest cognitive benefits with daily IV infusions; stroke trial results have been more variable.
• Generally well tolerated in short-term use; occasional mild injection-site reactions may occur with subcutaneous administration.
• Rare reports of dizziness, headache, or gastrointestinal upset; the master sheet directs that dosing be discontinued and a professional consulted if significant adverse effects occur.
• Route and dose gap: the published human evidence comes from the commercial premixed solution at daily amounts starting around 215 mg and running up through higher intravenous infusions, while this protocol is a conservative subcutaneous approach at 20 to 32 mg daily, so the two are not directly comparable.

Lifestyle Factors

Complementary strategies for best outcomes.

• Maintain a nutrient-dense diet rich in omega-3 fatty acids, antioxidants, and B-vitamins.
• Engage in regular aerobic exercise and cognitive stimulation to reinforce neuroplasticity.
• Prioritize quality sleep of 7 to 9 hours and stress management to optimize recovery and brain function.
• Avoid excessive alcohol and other neurotoxic substances during the protocol.

Injection Technique

General subcutaneous guidance from clinical best-practice resources.

1. Clean the vial stopper and skin with alcohol; allow to dry.
2. Pinch a 2 to 4 cm skinfold; insert the needle at 45 to 90 degrees into subcutaneous tissue.
3. Do not aspirate for subcutaneous injections; inject slowly and steadily.
4. Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy.
5. For split-dose protocols (AM/PM), use different injection sites for each administration.

References

Source citations for further reading.

1. Meta-analysis of Cerebrolysin efficacy in acute ischemic stroke (Med Sci Monit, 2017).
2. Neuroprotective action of Cerebrolysin in acute/chronic brain ischemia (PLOS One, 2021).